pentamidine &#160; Xi Nghezi (Q416206)

publication date ^{Xi Nghezi}

17 Hukuri 2015

DrugBank ID ^{Xi Nghezi}

00738

chemical structure ^{Xi Nghezi}

Pentamidine-skeletal.svg
512 × 135; 6 KB

0 references

ntikelo

340.19 dalton

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

chemical formula ^{Xi Nghezi}

C₁₉H₂₄N₄O₂

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

canonical SMILES ^{Xi Nghezi}

C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

active ingredient in ^{Xi Nghezi}

NebuPent ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

RxNorm ^{Xi Nghezi}

RxNorm ID ^{Xi Nghezi}

218646

retrieved ^{Xi Nghezi}

14 Nyenyenyani 2018

World Health Organisation international non-proprietary name ^{Xi Nghezi}

pentamidine (Xi Nghezi)

1 reference

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

medical condition treated ^{Xi Nghezi}

parasitic protozoa infectious disease ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

visceral leishmaniasis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

trypanosomiasis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

pneumocystosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

Leyiximeniyasisi

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

significant drug interaction ^{Xi Nghezi}

terfenadine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

procainamide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

chloroquine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

amiodarone ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

anagrelide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

arsenic trioxide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

astemizole ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

azithromycin ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

bepridil ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

chlorpromazine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

cisapride ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

(RS)-citalopram ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

clarithromycin ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

cocaine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

dofetilide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

domperidone ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

dronedarone ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

droperidol ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

erythromycin ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

escitalopram ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

flecainide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

halofantrine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

haloperidol ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

ibutilide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

mesoridazine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

(RS)-methadone ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

moxifloxacin ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

ondansetron ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

pimozide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

probucol ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

quinidine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

sevoflurane ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

sotalol ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

sparfloxacin ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

(RS)-sulpiride ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

thioridazine ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

High-priority drug–drug interactions for use in electronic health records ^{Xi Nghezi}

amiodarone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

arsenic trioxide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sotalol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

erythromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

clarithromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

levomepromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

droperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fluphenazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

chlorpromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

ondansetron ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

anagrelide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

moxifloxacin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

dronedarone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

vandetanib ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

crizotinib ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

pimozide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

zuclopenthixol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

pasireotide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

(RS)-methadone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

(RS)-hydroxyzine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

(RS)-citalopram ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

(RS)-sulpiride ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

haloperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

foscarnet ^{Xi Nghezi}

side effect ^{Xi Nghezi}

nephrotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

foscarnet ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hypocalcaemia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

trimethoprim ^{Xi Nghezi}

side effect ^{Xi Nghezi}

nephrotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

tacrolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

nephrotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

arsenic trioxide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

bone marrow failure ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

trimethoprim ^{Xi Nghezi}

side effect ^{Xi Nghezi}

bone marrow failure ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sulfamethoxazole ^{Xi Nghezi}

side effect ^{Xi Nghezi}

bone marrow failure ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

crizotinib ^{Xi Nghezi}

side effect ^{Xi Nghezi}

bone marrow failure ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

amiodarone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

amiodarone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

amiodarone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

arsenic trioxide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

arsenic trioxide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

arsenic trioxide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sotalol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sotalol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sotalol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

trimethoprim ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

trimethoprim ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

trimethoprim ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

trimethoprim ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

erythromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

erythromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

erythromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

clarithromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

clarithromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

clarithromycin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sulfamethoxazole ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sulfamethoxazole ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sulfamethoxazole ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sulfamethoxazole ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

levomepromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

levomepromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

levomepromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

droperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

droperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

droperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fluphenazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fluphenazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fluphenazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

chlorpromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

chlorpromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

chlorpromazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

tacrolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

(RS)-sulpiride ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

haloperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

haloperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

haloperidol ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

pregnancy category ^{Xi Nghezi}

US pregnancy category C ^{Xi Nghezi}

1 reference

imported from Wikimedia project ^{Xi Nghezi}

English Wikipedia ^{Xi Nghezi}

subject has role ^{Xi Nghezi}

antifungal ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Medical Subject Headings ^{Xi Nghezi}

MeSH descriptor ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

15 Nyenyankulu 2018

antiprotozoal ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Medical Subject Headings ^{Xi Nghezi}

MeSH descriptor ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

15 Nyenyankulu 2018

trypanocidal agent ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Medical Subject Headings ^{Xi Nghezi}

MeSH descriptor ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

15 Nyenyankulu 2018

essential medicine ^{Xi Nghezi}

0 references

bactericide ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)

Ntlawa wa Commons

Pentamidine

0 references

Identifiers

InChI ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

XDRYMKDFEDOLFX-UHFFFAOYSA-N

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

InChIKey ^{Xi Nghezi}

2 references

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

stated in ^{Xi Nghezi}

ChEBI release 2020-09-01 ^{Xi Nghezi}

CAS Registry Number ^{Xi Nghezi}

100-33-4

2 references

stated in ^{Xi Nghezi}

UNII ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

XDRYMKDFEDOLFX-UHFFFAOYSA-N

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

InChIKey ^{Xi Nghezi}

stated in ^{Xi Nghezi}

CAS Common Chemistry ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

8 Dzivamusoko 2021

reference URL ^{Xi Nghezi}

https://commonchemistry.cas.org/detail?cas_rn=100-33-4

ChemSpider ID ^{Xi Nghezi}

4573

1 reference

stated in ^{Xi Nghezi}

ChemSpider ^{Xi Nghezi}

ChemSpider ID ^{Xi Nghezi}

4573

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

PubChem CID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

Reaxys registry number ^{Xi Nghezi}

3159790

1 reference

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

ChEBI ID ^{Xi Nghezi}

mapping relation type ^{Xi Nghezi}

exact match ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ChEMBL ^{Xi Nghezi}

ChEMBL ID ^{Xi Nghezi}

CHEMBL55

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

PENTAMIDINE (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

ChEMBL ID ^{Xi Nghezi}

CHEMBL55

1 reference

stated in ^{Xi Nghezi}

ChEMBL ^{Xi Nghezi}

ChEMBL ID ^{Xi Nghezi}

CHEMBL55

language of work or name ^{Xi Nghezi}

splash10-0006-0009000000-18ffa88d8e83e0c224b3

title ^{Xi Nghezi}

PENTAMIDINE (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

SureChEMBL ID ^{Xi Nghezi}

SCHEMBL3329

1 reference

based on heuristic ^{Xi Nghezi}

inferred from InChIKey ^{Xi Nghezi}

UniChem compound ID ^{Xi Nghezi}

12557

1 reference

stated in ^{Xi Nghezi}

UniChem ^{Xi Nghezi}

MassBank accession ID ^{Xi Nghezi}

MSBNK-Fiocruz-FIO00450

0 references

MSBNK-Fiocruz-FIO00451

0 references

MSBNK-Fiocruz-FIO00452

0 references

MSBNK-Fiocruz-FIO00453

0 references

MSBNK-Fiocruz-FIO00454

0 references

MSBNK-Keio_Univ-KO003937

0 references

MSBNK-Keio_Univ-KO003938

0 references

MSBNK-Keio_Univ-KO003939

0 references

MSBNK-Keio_Univ-KO003940

0 references

MSBNK-Keio_Univ-KO003941

0 references

MSBNK-Keio_Univ-KO009179

0 references

MSBNK-Keio_Univ-KO009180

0 references

MSBNK-Keio_Univ-KO009181

0 references

SPLASH ^{Xi Nghezi}

0 references

splash10-00di-0309000000-22a206e2fffa6ce5cf2f

0 references

splash10-00dr-0900000000-d135e9c44dbf5da10735

0 references

splash10-00di-0900000000-d01e29cdf614c3660180

0 references

splash10-0006-0009000000-1499530d0d768e480fd7

0 references

splash10-0006-0009000000-3c60569ced478a95001f

0 references

splash10-00di-0209000000-58a168dde59140860009

0 references

splash10-00dr-0901000000-7cd36861b140e4e5a6a2

0 references

splash10-00di-0900000000-60dfcd75868e869bcbf7

0 references

splash10-00di-0009000000-6677c6c06aa266d05ff1

0 references

splash10-00dr-0903000000-140ddf0bc9583ef7ea2b

0 references

splash10-00kr-6900000000-e0a164c7a34de0798880

0 references

HSDB ID ^{Xi Nghezi}

7474

1 reference

stated in ^{Xi Nghezi}

Hazardous Substances Data Bank ^{Xi Nghezi}

HSDB ID ^{Xi Nghezi}

7474

publication date ^{Xi Nghezi}

28 Nhlangula 2019

title ^{Xi Nghezi}

PENTAMIDINE (Xi Nghezi)

retrieved ^{Xi Nghezi}

10 Mudyaxihi 2021

DSSTox substance ID ^{Xi Nghezi}

DTXSID7023431

1 reference

stated in ^{Xi Nghezi}

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard ^{Xi Nghezi}

DSSTOX compound identifier ^{Xi Nghezi}

DTXCID403431

0 references

NSC number ^{Xi Nghezi}

9921

0 references

EC number ^{Xi Nghezi}

202-841-0

1 reference

stated in ^{Xi Nghezi}

UNII ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

ECHA Substance Infocard ID ^{Xi Nghezi}

100.002.583

1 reference

stated in ^{Xi Nghezi}

ECHA Substance Infocard database ^{Xi Nghezi}

ECHA Substance Infocard ID ^{Xi Nghezi}

100.002.583

retrieved ^{Xi Nghezi}

27 N'wendzamhala 2018

title ^{Xi Nghezi}

Pentamidine (Xi Nghezi)

quotation ^{Xi Nghezi}

CAS no.: 100-33-4 (Xi Nghezi)

MeSH descriptor ID ^{Xi Nghezi}

subject named as ^{Xi Nghezi}

Pentamidine

0 references

MeSH concept ID ^{Xi Nghezi}

M0016169

0 references

MeSH tree code ^{Xi Nghezi}

D02.078.100.700

0 references

RxNorm ID ^{Xi Nghezi}

7994

1 reference

stated in ^{Xi Nghezi}

UNII ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

DrugBank ID ^{Xi Nghezi}

00738

1 reference

stated in ^{Xi Nghezi}

DrugBank ^{Xi Nghezi}

DrugBank ID ^{Xi Nghezi}

00738

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

Pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

Human Metabolome Database ID ^{Xi Nghezi}

HMDB0014876

1 reference

based on heuristic ^{Xi Nghezi}

inferred from InChIKey ^{Xi Nghezi}

UNII ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

UNII ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

MedlinePlus drug identifier ^{Xi Nghezi}

a685029

route of administration ^{Xi Nghezi}

intramuscular injection ^{Xi Nghezi}

intravenous injection ^{Xi Nghezi}

0 references

a601208

route of administration ^{Xi Nghezi}

inhalation administration ^{Xi Nghezi}

0 references

NDF-RT ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

UNII ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

17 Hukuri 2016

Probes And Drugs ID ^{Xi Nghezi}

PD010048

0 references

DrugCentral ID ^{Xi Nghezi}

2090

1 reference

stated in ^{Xi Nghezi}

UniChem ^{Xi Nghezi}

KEGG ID ^{Xi Nghezi}

D08333

1 reference

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

https://docs.openalex.org/download-snapshot/snapshot-data-format

title ^{Xi Nghezi}

pentamidine (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

PDB ligand ID ^{Xi Nghezi}

PNT

0 references

electronic Essential Medicines List medicine ID ^{Xi Nghezi}

386

0 references

Freebase ID ^{Xi Nghezi}

/m/015mv7

1 reference

stated in ^{Xi Nghezi}

Freebase Data Dumps ^{Xi Nghezi}

publication date ^{Xi Nghezi}

28 Nhlangula 2013

Microsoft Academic ID ^{Xi Nghezi}

2777530519

0 references

OpenAlex ID ^{Xi Nghezi}

C2777530519

1 reference

stated in ^{Xi Nghezi}

OpenAlex ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

26 Sunguti 2022

reference URL ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

3GY3

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

3GY3

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

3GY3 (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

1D64

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

1D64

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

1D64 (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

3HII

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

3HII

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

3HII (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

3CR4

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

3CR4

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

3CR4 (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

3CR5

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

3CR5

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

3CR5 (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

1RKW

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

1RKW

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

1RKW (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

3EY0

1 reference

stated in ^{Xi Nghezi}

Protein Data Bank ^{Xi Nghezi}

PDB structure ID ^{Xi Nghezi}

3EY0

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

3EY0 (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Nhlangula 2016

UMLS CUI ^{Xi Nghezi}

C0030863

1 reference

stated in ^{Xi Nghezi}

UNII ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}